- Wednesday, October 16, 2024
Exelixis, in collaboration with Ipsen, has revealed positive findings from a phase 3 clinical trial that assessed the effectiveness of cabozantinib and atezolizumab in treating metastatic castration-resistant prostate cancer. The primary objective of the trial, progression-free survival, was successfully met. However, the data did not show statistical significance in terms of overall survival.
After conducting a comprehensive analysis, the trial demonstrated a significant improvement in progression-free survival. Although there was a positive trend in overall survival outcomes, it did not reach statistical significance in the study.
Despite these results, Exelixis and Ipsen plan to continue the trial and conduct further analysis on overall survival. The trial evaluated the combination of cabozantinib and atezolizumab compared to a novel hormonal therapy. Exelixis sponsored the study and received co-funding from Ipsen, Roche Holding, and Takeda Pharmaceutical.
These findings bring promising advancements in the field of prostate cancer treatment. Researchers and medical professionals will continue to closely monitor the progress of the trial for potential breakthroughs.
More Posts
All Rights Reserved © 2024
Post a comment